Recent improvements in mRNA and immunogenicity

Vaccines avoid many illnesses and save many lives every year. As a result of common vaccine use, the smallpox virus has entirely been eradicated and the occurrence of measles, polio and other childhood diseases have considerably been abridged around the world. Classical vaccine strategies, for instance inactivated pathogen, live attenuated and subunit vaccines, offer strong protection against diversity of hazardous diseases. In spite of this achievement, there remain chief obstacles to vaccine development against a diversity of infectious pathogens, part-icularly those better able to avoid the adaptive immune response. Furthermore, for most emer-ging virus vaccines, the main barrier is not the efficiency of usual approaches but the requirements for more rapid development and large-scale use. Nucleic acid therapeutics have appeared as hopeful option to classical vaccine approaches.